EVALUATING THE IMPACT OF MYOCARDITIS IN PEDIATRIC PATIENTS: A CROSS-SECTIONAL STUDY FROM A LOW-RESOURCE SETTING
Main Article Content
Keywords
Pediatric Myocarditis, Heart Failure, Low-Resource Settings, Cardiac Dysfunction
Abstract
Background: Pediatric myocarditis is a significant cause of heart failure and associated mortality in children, particularly in low-resource settings like Pakistan where diagnostic and treatment challenges are more pronounced. The purpose of this study is to evaluate pediatric myocarditis prevalence, clinical characteristics, treatment modalities, and results at a Pakistani tertiary care facility.
Objectives: to assess the prevalence, clinical characteristics, treatment approaches, and short-term outcomes of pediatric myocarditis in a low-resource setting at a Pakistani tertiary care hospital.
Study Design: A cross-sectional study
Methods: A cross-sectional study was conducted from August to October 2023 at the Pediatric Cardiology Department, Lady Reading Hospital, Peshawar. In this study a total of 104 children, between the ages of 1 and 16 diagnosed with myocarditis were examined based on echocardiographic and lab criteria. The data collected included information on demographics symptoms upon presentation, diagnostic results, treatment approaches and short term outcomes.
Results: Among the 104 patients studied 65 were male (62%) with an age of 7.9 years (ranging from 1 to 16 years). Most patients (85%) presented symptoms of heart failure such as difficulty breathing, fatigue and swelling in extremities. Echocardiograms indicated left dysfunction in 73 individuals (70%) with a mean ejection fraction of 32% (+/ 12%).IV immunoglobulin (IVIG) therapy was used as one of the management methods for 44% (n=46) of the patients. Just 50% (n=23) of patients receiving IVIG, however, saw appreciable improvements in their cardiac function. Only 8% (n=8) of patients had access to mechanical circulatory support due to resource limitations, which restricted the utilization of advanced heart failure therapy. Cardiogenic shock was the leading cause of death, accounting for 18% of the total mortality rate (n = 19). At the 3-month follow-up, 59% of survivors (n=50) still had left ventricular dysfunction, indicating the long-term effects of the illness.
Conclusion: In conclusion this research underscores the toll of myocarditis in areas with limited resources. The high mortality rate, lack of access to treatments and the prevalence of heart issues underscore the importance of early detection easier access to therapies and preventive measures such as vaccinations, against common viruses.
References
2. Fairweather D, Cooper LT, Blauwet LA. Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol. 2013;38(1):7-46.
3. Baughman KL. Diagnosis of myocarditis: death of Dallas criteria. Circulation. 2006;113(4):593-595.
4. Ammirati E, Cipriani M, Lilliu MA, et al. The diagnosis and management of acute myocarditis in children. Expert Rev Cardiovasc Ther. 2020;18(9):505-512.
5. Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636-2648.Cooper LT Jr. Myocarditis. N Engl J Med. 2009;360(15):1526-1538.
6. Robinson J, Hartling L, Vandermeer B, et al. Intravenous immunoglobulin for presumed viral myocarditis in children and adults. Cochrane Database Syst Rev. 2020;5(5)
7. Menteer J, Avula S, Morgan GJ, et al. The utility of mechanical circulatory support in children with myocarditis. J Pediatr. 2019;207:42-49.
8. Wilkinson JD, Van Houten AC, Dennis M, et al. Myocarditis in children: an overview. Curr Treat Options Cardiovasc Med. 2013;15(4):379-391.
9. Gagliardi MG, Bevilacqua M, Di Renzi P, et al. Myocarditis in the pediatric age group: clinical features, diagnostic criteria, and therapy. Eur J Pediatr. 2003;162(2):84-92.
10. Ammirati E, Cipriani M, Lilliu MA, et al. The diagnosis and management of acute myocarditis in children. Expert Rev Cardiovasc Ther. 2020;18(9):505-512.
11. Wilkinson JD, Van Houten AC, Dennis M, et al. Myocarditis in children: an overview. Curr Treat Options Cardiovasc Med. 2013;15(4):379-391.
12. Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636-2648.
13. Cooper LT Jr. Myocarditis. N Engl J Med. 2009;360(15):1526-1538.
14. Fairweather D, Cooper LT, Blauwet LA. Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol. 2013;38(1):7-46.
15. Robinson J, Hartling L, Vandermeer B, et al. Intravenous immunoglobulin for presumed viral myocarditis in children and adults. Cochrane Database Syst Rev. 2020;5(5)
16. Menteer J, Avula S, Morgan GJ, et al. The utility of mechanical circulatory support in children with myocarditis. J Pediatr. 2019;207:42-49.
17. Baughman KL. Diagnosis of myocarditis: death of Dallas criteria. Circulation. 2006;113(4):593-595.
18. Ammirati E, Veronese G, Cipriani M, et al. Acute and fulminant myocarditis: a pragmatic clinical approach to diagnosis and treatment. Curr Cardiol Rep. 2018;20(8):63.